Aposense, a developer of agents targeting apoptosis for molecular imaging and therapy, has formed a collaboration with the London-based GlaxoSmithKline to evaluate the potential of Aposense's PET tracer ML-10 in monitoring drug activity in clinical studies of cancer therapies.

The project is intended to assess the contribution of ML-10 in accelerating clinical development of cancer therapies, according to the Petach-Tikva, Israel-based Aposense.

The initial term of the non-exclusive collaboration is for two years, and can be extended on certain conditions. Financial terms of the agreement were not disclosed.